Nxera Pharma to Receive US$3 Million Milestone Payment from Centessa Pharmaceuticals

Core Insights - Nxera Pharma has announced a milestone achievement by Centessa Pharmaceuticals related to the development of ORX489, an orexin receptor 2 agonist for neuropsychiatric disorders, resulting in a payment of US$3 million to Nxera [1] - The milestone payment will be recognized as revenue in the first quarter of 2026 [1] Company Overview - Nxera Pharma is a technology-driven biopharma company focused on developing specialty medicines for unmet patient needs in Japan and globally [2] - The company operates a new-generation commercial business in Japan, aiming to develop and commercialize innovative medicines in a growing market [2] - Nxera Pharma has a diverse pipeline and collaborates with leading pharmaceutical and biotech companies, utilizing its NxWave™ GPCR structure-based drug discovery platform [2] - The company has key operational locations in Tokyo, Osaka, London, Cambridge, Basel, and Seoul, and is listed on the Tokyo Stock Exchange under ticker 4565 [2]